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Purpose. Idiopathic Carpal Tunnel Syndrome (CTS) is the most common 
entrapment neuropathy; however few and only retrospective studies have 
been found in search engines about Ozone Therapy.  The aim of this paper 
was to evaluate clinical and neurophysiological outcome following Ozone 
Therapy in CTS. We focused the attention on the evidences concerning the 
role of Subsynovial Connective Tissue (SSCT) in the pathogenesis of CTS 
and the ozone pre-conditioning effects linked to pain and inflammatory 
pathways and to fibrosis induced by Ischemia-Reperfusion Injury.
Materials and methods. Thirty-five patients, aged between 21 and 80, were 
stratified clinically by Boston Carpal Tunnel Questionnaire (B.C.T.Q.) and 
Neurophysiologically by Padua’s Gravity Scale classifying patients into five 
Electro-myographic categories. The mean symptom duration was also 
recorded. The patients filled in the B.C.T.Q. before and after treatment as 
well underwent diagnostic neurophysiological tests, strictly standardized in 
stimulation parameters, electrodes placement and skin temperature. The 
Ozone Therapy was performed by injecting 4 ml of O2-O3 mixture at 10 ug/
ml concentration under the transverse carpal ligament twice a week for eight 
sessions. 
Results. We compared the B.C.T.Q. scores and the neurophysiological 
parameters obtained before and after O2-O3 treatment: the improvement of 
symptoms was significantly greater than the improvement of motor and 
sensory nerve conduction. The highest clinical improvement degree was 
found in patients classified in Mild and Moderate Groups.
Discussion and Conclusion. Ischemia-Reperfusion Injury triggers oxidative 
stress in SSCT with activation of chemical mediators and neo-angiogenesis 
leading to non-inflammatory fibrosis that represent the allmark of CTS. 
Previous and retrospective studies based O2-O3 treatment on the main 
mechanisms of action shared by the treatment of herniated disc in the spine; 
our study focused the attention on pathophysiology of the SSCT trying to 
recognize the various stages of CTS pathogenesis by correlating with clinical 
and neuro-physiological tests. Further studies have to be carried out to 
better understand these relationships and optimize timing of Ozone Therapy.
Keywords:  Ozone therapy, carpal tunnel syndrome, ischemia reperfusion injury, oxidative 
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Idiopathic Carpal Tunnel Syndrome (CTS) is the most common entrapment 
neuropathy; however, inquiring the main search engines, only few and 
retrospective studies [37,44] are available about Ozone Therapy.
In these papers O2-O3 treatment is based on three main mechanisms of 
action shared by the treatment of herniated disc in the spine: a) indirect 
vessel-mediated mechanical decompression of the nerve roots by increasing 
intra and trans-tissue oxygenation with reduced hypoxia and venous and 
lymphatic stasis 22;  b) action on the cell-mediated inflammatory response 
both by inhibiting the release of proteinase by macrophages and 
polymorphonucleates and by increasing immunosuppressive cytokines 
(interleukin 10, TGF-beta); c) action on the bio-humoral inflammatory 
response, inhibiting the release of prostaglandins and pro-inflammatory 
bradykinins
Conversely we have got plenty of papers about pathophysiology of Sub-
Synovial Connective Tissue (SSCT) in CTS.
It is widely accepted that repetitive motion of the wrist, hand and fingers can 
lead to CTS by a shear strain sufficient to injure the SSCT, triggering a non-
inflammatory fibrosis of the subsynovial connective tissue, as his histo-
morphological hallmark.
In the last decade several Authors focused their attention on the different 
biochemical and vascular pathways that characterize the different stages 
leading to SSCT fibrosis [9,11,13, 14,15,16 17,18,27,39,40,43].
We can recognize the early stages by tenosynovial swelling in MRI image [41].
The oxidative stress in subsynovial connective tissue, caused by repeated 
transient ischemia-reperfusion injury (IRI), was demonstrated by high levels 
of MDA ( MalonilDiAldehyde, a marker of lipid membrane peroxidation ), up-
regulation of eNOS ( endothelial Nitric Oxide Synthase ) and activation of 
NF-kb ( a marker of cells immunoreactivity ), with significant positive 
correlation between subjective symptom severity and immunoreactivities of 
eNOS and NF-kb [27].
The early stages of CTS are also featured by: a) IL-6 cytokine activation, that 
leads to inflammatory modulation, stimulation of fibroblastic proliferation and 
increased sensitivity of nerve endings to pain [36]; b) PGE2 production, that 
enhances vascular permeability and increases sensitization of nerve endings 
leading to allodynia, and c) VEGF expression (Vascular Endothelial Growth 
Factor) that again increases vascular permeability, triggering neo-
angiogenesis. [9,11,21]
In the intermediate stages of CTS the histological findings in tenosynovium 
change from edematous to fibrotic.
Various cytokines and growth factors are involved in the development of 
fibrosis, but TGF-β1 is considered to be the most potent and ubiquitous pro 
fibrogenic cytokine and its signalling and fibrotic gene expression is 
upregulated in Carpal Tunnel Syndrome [17,18].
Transforming Growth Factor β1 and CTGF (Connective Tissue Growth 
Factor, a cysteine rich peptide) play a synergistic action to promote chronic 
fibrosis by progressive deposition of Extra Cellular Matrix (ECM) and 
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degradation and increasing fibrosis [9,39].
It is our knowledge that Ozone Therapy plays a protective role against 
Ischemia Reperfusion Injury (I.R.I.) [25,26,28,30,31,42] through triggering 
the antioxidant capacity with increase of SOD and GSH values and reducing 
the expression of “TLR4-NF-Kb pathway“, with decrease of inflammatory 
molecules and leukocyte recruitment [6].
Several studies  showed that Ozone promotes wound healing via induction 
of Vascular Endothelial Growth Factor (VEGF), Transforming Growth Factor 
Beta (TGF-β1) an Platelet-Derived Growth Factor (PDGF), according with 
the studies of Professor Bocci that demonstrated significantly increase and 
release of PDGF, TGF- β1 and VEGF in presence of Ozone [3,4,46].
We also known that “ozone-induce airway fibrosis” is mediated by increased 
TGF- β1 expression [2].
The aim of the present paper was to design a prospective study to evaluate 
clinical and neurophysiological outcome following Ozone Therapy in CTS, 
focusing on the evidences concerning the role of Subsynovial Connective 
Tissue (SSCT) in the pathogenesis of CTS and trying to temporarily correlate 
our findings to the effects of ozone on pain and inflammatory pathways and 
to the different stages characterizing fibrosis induced by Ischemia-
Reperfusion Injury.
Materials and methods 
We designed the first prospective study to evaluate clinical and 
neurophysiological outcome following Ozone Therapy in CTS, focusing our 
attention on pathophysiology of SSCT surrounding the flexor tendons in 
Carpal Tunnel.
We studied thirty-five consecutive patients, 25 women and 10 men, for a 
total amount of 70 hands, aged between 21 and 80, with History, Clinical and 
Neurophysiological coherence for idiopathic CTS. All patients underwritten 
informed consent to treatment.
Patients with other mononeuropathy or polyneuropathy, radiculopathy, 
systemic comorbidity (such as diabetes, endocrine diseases, inflammatory 
arthritis or renal failure), previous surgery and concomitant tendinopathies 
were excluded.
All patients had diagnostic neurophysiological testing, performed using 
System Plus Evolution by Micromed (Mogliano Veneto, Italy), including 
electromyography and sensory/motor nerve conduction studies, performed 
before and after Ozone Therapy, following stringent standardization criteria 
regarding electrodes placement, stimulation parameters and skin 
temperature.
Electrodiagnostic findings allowed us to classify the patients into five Groups 
following the Padua Neurophysiological Classification of CTS [33], as shown 
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Subjective symptom severity was measured using the 11-items Boston 
Carpal Tunnel Questionnaire (B.C.T.S.) [24,32,34], filled in before and after 
treatment and the mean symptom duration was also recorded.
The Ozone Therapy was performed by injecting (Fig.1), with a 23 G needle 
and Antimicrobial filter, 4 mL of O2-O3 mixture at 10 ug/mL concentration 
(produced by Herrmann Medozon Compact in Elsenfeld, Germany) under 
the transverse carpal ligament, twice a week for eight sessions. 
Statistical Analysis
Each patient was assigned to a specific group according to the Padua’s 
classification and for each group a, two-tailed, z-test was performed.
Results are represented in tables 2 and 3 as mean values and mean 
difference (MD), between values found at diagnosis (Pre) and those after 
treatment (Post), is applied. Confidence interval of 95% is shown above and 
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Fig.1. The Ozone Therapy was performed by injecting
Table 1. Padua’s Classification
Minimal (n 9) Relative slowdown  in comparative sensory test at IV finger vs 
ulnar nerve 
Mild (n 29) Sensory slowdown in the palm wrist section with normal value of 
motor latency
Moderate (n 20) Sensory slowdown in the palm wrist section with slight/moderate 
increased motor latency
Severe (n 15) Absence of Sensory Action Potential (SAP) with severe increase  
of motor latency 
Extreme (n 0) Absence of Sensory Action Potential (SAP)  and Motor Action 
Potential ( MAP )
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Results 
We compared the B.C.T.Q. scores and the neurophysiological parameters 
obtained before and after O2-O3 treatment.
Due to the low sample size, we excluded from statistical analysis patients 
classified into severe Padua’s group (table 1); the majority of patients were 
classified into mild and moderate groups in which we also found the highest 
clinical improvement degree.  
The statistical analysis demonstrated that the improvement of symptoms 
was significantly greater than the improvement of motor and sensory nerve 
conduction, according to the previous findings [8,32] about subjective 
symptoms that not always depend on median nerve functional status or 
symptom durations and are not always reflected by findings from 
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Table 2 Shows data resulting from the electromyographic evaluation of motor distal latency (MDL) and sensitivity 
conduction speed (SCS).
Minimal
Pre Post MD SD Z-test P-value 95% CI
MDL 3,500 3,456 0,044 0,093 0,956 0,171 -0,138 / 0,227
SCS 46,511 47,900 1,389 1,407 1,974 0,024 -1,369 / 4,147
Mild
Pre Post MD SD Z-test P-value 95% CI
MDL 3,683 3,575 0,108 0,056 3,892 <0,0005 -0,001 / 0,217
SCS 41,950 44,400 2,450 1,849 2,651 0,004 -1,173 / 6,073
Moderate
Pre Post MD SD Z-test P-value 95% CI
MDL 4,556 4,344 0,211 0,054 7,817 <0,0005 0,105 / 0,317
SCS 37,614 39,869 2,256 1,035 4,358 <0,0005 0,227 / 4,285
Table 3  Shows data obtained through the Boston CTS Questionnaire (BCTQ).
Minimal
Pre Post MD SD Z-test P-value 95% CI
15,714 6,714 9,000 1,759 10,231 <0,0005 5,552 / 12,448
Mild
Pre Post MD SD Z-test P-value 95% CI
15,600 2,800 12,800 3,323 7,705 <0,0005 6,288 / 19,132
Moderate
Pre Post MD SD Z-test P-value 95% CI
19,056 9,000 10,056 2,057 9,775 <0,0005 6,023 / 14,088
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Discussion 
Carpal Tunnel Syndrome (CTS) is currently the most frequently encountered 
peripheral compressive neuropathy.  

Clinical and animal models demonstrated the pivotal role of Sub-Synovial 
Connective Tissue (SSCT) in the pathogenesis of the “idiopathic CTS”.

Histo-morphological hallmarks in CTS is a non-inflammatory fibrosis in 
SSCT, surrounding flexor tendons, leading to the common final pathway for 
the development of CTS, with increase in interstitial fluid pressure within the 
carpal canal and the median nerve, owing to microcirculatory venous stasis 
in a confined space.

Many previous studies showed that ischemia-reperfusion injury (IRI) can be 
considered the “primum movens” of CTS: in fact the oxidative stress 
caused by IRI (as well as in many other diseases) triggers a cascade of 
events characterized by cytokine production in fibroblast and endothelial 
cells, with vascular hypertrophy and subsequent tissue fibrosis.

Kim, Seol et al. [19,27] emphasized a significant positive correlation 
between the subject ive symptoms severity of CTS and the 
immunoreactivities of eNOS and NF-κβ. Such evidence suggests that 
oxidative stress in subsynovial connective tissues contributes to the 
subjective symptoms, according with previous papers that related clinical 
aspects to tenosynovial oedematous swelling and MMP-2 activation, 
especially in the early stages of the disease.

The cascade of events triggered by IRI leads to intermediate stages of CTS 
in which the histological findings in tenosynovium change from edematous 
to fibrotic.

Several Authors have identified the increased expression of fibrotic factors 
such as transforming growth factor - beta (TGF-β1), connective tissue 
growth factor, (CTGF), type 1 collagen (Col1) and type 3 collagen (Col3) in 
the SSCT from CTS patients.

Latest studies explored the nature of the fibrotic expression found in the 
SSCT of patients with CTS and noted significantly increased gene 
expression for Col1 and 3, TGF-β and SMAD3 in CTS fibroblasts. These 
studies also examined blocking TGF-β signaling in CTS and suggest that 
therapies targeted for the TGF-β signaling pathway may ultimately have 
utility for the prevention and/or treatment of CTS as well as the anti-fibrotic 
effect of relaxin [22,23].

In the intermediated stages of CTS, many studies showed 
neovascularization and vascular pathologic changes mediated by VEGF 
activation: hypoxia downregulates tropoelastin gene expression with 
consequent decreased elastogenesis, triggering a vicious cycle of 
tenosynovial ischemia-reperfusion.         

We designed our study considering all the pathophysiological evidence in 
SSCT described above and reviewing the knowledge about ozone, 
especially regarding its interaction with pain mediators, its protective role 
against Ischemia Reperfusion Injury and its role in wound healing, as 
reported extensively in reference chapter.

As neurophysiological knowledge teaches us, sensory conduction velocity 
and motor latency provide information about myelin sheet which is first 
involved by pressure increasing in carpal tunnel confined space; the 
amplitude of Motor and Sensory Action Potentials ( cMAP and cSAP ) is 
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The majority of our patients was neurophysiologically classified in Mild and 
Moderate Padua’s groups: as shown in Table 2, in these groups we found a 
slight statistical improvement in motor and sensory parameters, according 
with low Confidence Interval. 

Evaluating the B.C.T.Q. score in Mild and Moderate groups (Table 3) the 
clinical improvement results highly statistical significant as shown by high 
Confidence Interval.

Minimal, mild and moderate Padua’s groups could represent the 
pathophysiological “early stages”, in which tenosynovial swelling leads to 
increasing pressure in carpal tunnel resulting in only slow speeds without 
reduction in amplitude that means no axonal loss.

The high improvement in clinical symptoms after Ozone therapy in mild and 
moderate groups could be explained by its documented protective effects 
against Ischemia-Reperfusion Injury and consequent oxidative stress 
cascade.

When histological findings in tenosynovium change from oedematous to 
fibrotic we could recognize the transition from early to intermediate stage, 
characterized by progressive thickening of the SSCT resulting in a steady 
increase in pressure that leads to progressive axonal degeneration.

Regarding the references about biological and therapeutic effects of Ozone 
there are many evidences in wound healing via induction of Vascular 
Endothelial Growth Factor (VEGF), Transforming Growth Factor Beta (TGF-
β1) and Platelet-Derived Growth Factor (PDGF), as previous demonstrated 
by studies of Professor Bocci [3,4].

This profibrotic action of ozone leads us to a critical evaluation of the use of 
ozone in intermediate stages of CTS, in which Transforming Growth Factor 
Beta (TGF-β1)is Upregulated , opening, conversely, doors for targeted drug 
therapies by blocking fibrotic signaling in fibroblasts in patients with CTS 
[22].

The present paper demonstrates that we need further prospective studies to 
define the optimal timing of Ozone Therapy, not only about CTS, regarding 
its biological complexity of action and its relationship with different stages in 
various diseases [38,45].  
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